ArticleCurrent medicinal chemistry2025
A Gene Signature Developed Based on Reactive Oxygen Species to Predict the Metabolism, Immunity, Mutational Status, and Prognostic Survival for Glioblastoma.
Article in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo explore the mechanism of regulatory genes related to reactive oxygen species (ROS) in glioblastoma (GBM).
backgroundGBM is a brain malignancy with a poor prognosis. ROS plays a critical role in cellular metabolism, signaling, and senescence, and abnormalities in ROS are closely associated with cancer initiation and development. However, the role of ROSregulated genes in GBM remained unknown.
objectiveTo explore the role of ROS-regulated genes in GBM and to build a ROS-related prognostic model.
methodsRNA sequencing data and clinical data from GBM patients were collected from public databases. The enrichment scores of ROS-correlated pathway gene sets obtained from The Molecular Signatures Database (MSiDB) were calculated using single sample gene set enrichment analysis (ssGSEA). Subsequently, key ROS-correlated gene modules were sectioned by weighted gene co-expression network analysis (WGCNA). Least absolute shrinkage and selection operator (LASSO) and Cox regression analyses were performed to screen ROS-related genes, which were used to develop a risk model. In addition, the correlation between patients in high-risk and low-risk groups and clinicopathological features, metabolism-related pathways, and pathways related to tumor progression was analyzed. Finally, the difference in immune cell infiltration between patients in the two risk groups was calculated using CIBERSORT.
resultsWe found that ROS-related genes could predict the prognosis of patients suffering from GBM and that abnormal activation of the ROS pathway increased the metabolism of sugars, fats, and amino acids. WGCNA identified gene modules closely associated with ROS. A prognostic risk model was created using three key genes (OSMR, SLC6A6, and UPP1). Immune infiltration analysis showed that high-risk Patients had higher levels of macrophage infiltration, and a high-RiskScore was positively correlated with multiple metabolism processes, programmed death, and epithelial-mesenchymal transition (EMT) pathway activity.
conclusionThe ROS-associated risk model could accurately predict tumor immunity and progression for GBM patients, acting as an effective predictor of GBM prognosis. The present discovery provided a novel understanding of the diagnosis and treatment of GBM patients.
Indexed as
Identifiers
40605162What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.